NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53 WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.

Autor:	Wong, Michael K.K., Burgess, Melissa Amber, Chandra, Sunandana, Fecher, Leslie Anne, Gaudy-Marqueste, Caroline, Silk, Ann W., Hanna, Glenn J., Lebbe, Celeste, Quéreux, Gaëlle, Rabinowits, Guilherme, Schadendorf, Dirk, Dutriaux, Caroline, Berking, Carola, Martin Liberal, Juan, Ascierto, Paolo Antonio, Houlihan, Emily, Steinmann, Kim, Chan, Tiffanie, Rothbaum, Wayne P., Kelly, Ciara Marie
Zdroj:	Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS9600-TPS9600, 1p
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu